doxazosin has been researched along with Extrasystole, Ventricular in 1 studies
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kamibayashi, T | 1 |
| Hayashi, Y | 1 |
| Mammoto, T | 1 |
| Yamatodani, A | 1 |
| Sumikawa, K | 1 |
| Yoshiya, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Guanfacine for PONV and Pain After Sinus Surgery[NCT02882854] | 84 participants (Actual) | Interventional | 2016-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02882854)
Timeframe: Time frame between arrival and discharge in PACU, approximately 90 minutes
| Intervention | minutes (Median) |
|---|---|
| Guanfacine | 128 |
| Placebo | 110 |
PONV assessed using nVRS at 24 hours postop when 0 is no nausea and 10 is worst nausea. (NCT02882854)
Timeframe: 24 hours post op
| Intervention | score on a scale (Median) |
|---|---|
| Guanfacine | 0.00 |
| Placebo | 0.00 |
Postoperative pain assessment using VAS at 24 hours postop when 0 is no pain and 10 is worst pain (NCT02882854)
Timeframe: 24 hours postop
| Intervention | score on a scale (Median) |
|---|---|
| Guanfacine | 3 |
| Placebo | 2 |
Total narcotic requirement in PACU tallied in morphine equivalents during PACU stay (NCT02882854)
Timeframe: Time frame between arrival and discharge in PACU, approximately 90 minutes
| Intervention | morphine equivalents (Median) |
|---|---|
| Guanfacine | 8.75 |
| Placebo | 7.50 |
Maximum postoperative pain assessment assessed in PACU at 15, 30 and 60 minutes after PACU arrival using VAS when 0 is no pain and 10 is worst pain (NCT02882854)
Timeframe: 15, 30, 60 minutes after arriving in PACU
| Intervention | Participants (Count of Participants) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15 minutes after PACU admission72482977 | 15 minutes after PACU admission72482978 | 30 minutes after PACU admission72482977 | 30 minutes after PACU admission72482978 | 60 minutes after PACU admission72482977 | 60 minutes after PACU admission72482978 | |||||||||||||
| Mild (Pain nVRS 1-5) | Moderate/Severe (Pain nVRS 6-10) | None (Pain nVRS 0) | ||||||||||||||||
| Guanfacine | 31 | |||||||||||||||||
| Placebo | 24 | |||||||||||||||||
| Guanfacine | 0 | |||||||||||||||||
| Placebo | 5 | |||||||||||||||||
| Guanfacine | 8 | |||||||||||||||||
| Placebo | 10 | |||||||||||||||||
| Guanfacine | 18 | |||||||||||||||||
| Placebo | 20 | |||||||||||||||||
| Guanfacine | 7 | |||||||||||||||||
| Placebo | 6 | |||||||||||||||||
| Guanfacine | 14 | |||||||||||||||||
| Placebo | 14 | |||||||||||||||||
| Guanfacine | 12 | |||||||||||||||||
| Placebo | 16 | |||||||||||||||||
| Guanfacine | 6 | |||||||||||||||||
| Placebo | 13 | |||||||||||||||||
| Guanfacine | 21 | |||||||||||||||||
| Placebo | 12 | |||||||||||||||||
1 other study available for doxazosin and Extrasystole, Ventricular
| Article | Year |
|---|---|
Role of the vagus nerve in the antidysrhythmic effect of dexmedetomidine on halothane/epinephrine dysrhythmias in dogs.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Anesthetics, Inhalation; Animals; Dogs; Dox | 1995 |